Apremilast for generalized epidermolysis bullosa simplex
Tests apremilast in people with generalized epidermolysis bullosa simplex, a skin blistering disease.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Where
- France5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 6 Aug 2024
- Planned end
- 1 Apr 2026
- Type of study
- Interventional
- Treatments tested
- Apremilast treatment
- Record updated
- 24 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 6 years or older with generalized severe epidermolysis bullosa simplex (EB simplex), a genetic skin blistering disease. All participants take apremilast.
- Age
- 6 Years to 99 Years
- Sex
- Male and female
- Disease stage
- Severe generalized EB simplex (EBS-sev), with on average more than 3 new blisters each day.
- Earlier treatment
- No diacerein products in the 6 months before Visit 1. No systemic immunotherapy or cytotoxic chemotherapy in the 60 days before Visit 1. No systemic steroids in the 30 days before Visit 1. Only skin treatments approved by the study doctor may be used.
- Biomarker or test result
- Laboratory-confirmed KRT5 or KRT14 mutation (autosomal).
Main reasons for not taking part
- Skin lesions with an infection that needs treatment by mouth
- Use of a diacerein product within 6 months before Visit 1
- Systemic immunotherapy or cytotoxic chemotherapy within 60 days before Visit 1
- Systemic steroids within 30 days before Visit 1
- Other whole-body medicines in the past 30 days that the study doctor thinks add risk or disturb study tests
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female patients 6 years or older
- Laboratory confirmed diagnosis of EBS-sev due to KRT5 or 14 mutation (autosomal)
- Mean daily number of new blisters >3
- Subject/caregiver agrees not to use any topical therapies other than the investigator approved
Who cannot take part
- Use of any diacerein containing product within 6 months prior to Visit 1
- Use of systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Visit 1
- Use of systemic steroidal therapy within 30 days prior to Visit 1
- Use of any systemic product that, in the opinion of the investigator, might put the subject at undue risk by study participation or interferes with the study assessments within 30 days prior to Visit 1
- - EBS lesions requiring oral therapy to treat an infection
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 99 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients > 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment.
Read full original descriptionShow less
Participants will take treatments and have to use bullets during the study period.
The group in the trial
- apremilast treatmentTreatment being tested
treatment by apremilast in two phases of challenge
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- EBULO. a 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 Years of Age with EB Simplex Generalized
- Plain-language title
- Apremilast for generalized epidermolysis bullosa simplexGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06509984, who can take part
- Publications
- Record updated
- 24 February 2025